The regulatory framework isnt as simple as that. You cant just do another trial and expect approval.
The FDA monitors such events. The fact of the matter is that there is a low probability of approval now.
Alchemia even states that they put in place adequate controls to monitor process and procedures with the assistance of the CRO.
There is a glimmer of hope if they can explain the Russian anomaly. But they cant..to date. Investigating this rubbish is some other company's job in my opinion. Alchemia should be focused on reducing opex and paying dividends. At this point I dont think they should be keeping staff on, just to flog off the other programmes/assets. They can do that later. Just get rid of 98% of everyone and pay-out. Its such a simple thing to do but they are hanging on for some unknown reason.
- Forums
- ASX - By Stock
- ACL should try to replace Russian 3rd trial result with new other country's trial result
TSN
the sustainable nutrition group ltd
Add to My Watchlist
0.00%
!
1.0¢

The regulatory framework isnt as simple as that. You cant just...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online